SEC Form 4 · accession 0001225208-18-015657
BOSTON SCIENTIFIC CORP · BSX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Maulik Nanavaty
Officer — SVP & Pres, Neuromodulation
Period of report
Nov 16, 2018
Accepted (ET)
Nov 19, 2018 · 4:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 16, 2018 | M | 23,458 | $8.30 | A | 256,809 | D | |
| Common StockF2,F1 | Nov 16, 2018 | S | 23,458 | $37.2771 | D | 233,351 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $8.30 | Nov 16, 2018 | M | 23,458 | D | — | Feb 24, 2019 | Common Stock | 23,458 | 0 | D |
Explanation of responses
- F1Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
- F2Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.27 to $37.30, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Grant to the reporting person of an option to purchase a specified number of common stock vesting in four equal annual installments beginning on February 24, 2010, the first anniversary of the date of grant.